Co-Diagnostics Inc
NASDAQ:CODX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.01
1.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Co-Diagnostics Inc
Co-Diagnostics Inc
Long-Term Debt
Co-Diagnostics Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Co-Diagnostics Inc
NASDAQ:CODX
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Long-Term Debt
$17.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
17%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Long-Term Debt
$9.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Long-Term Debt
$13.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
11%
|
CAGR 10-Years
15%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Long-Term Debt
$13.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
13%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Co-Diagnostics Inc
Glance View
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
See Also
What is Co-Diagnostics Inc's Long-Term Debt?
Long-Term Debt
0
USD
Based on the financial report for Sep 30, 2024, Co-Diagnostics Inc's Long-Term Debt amounts to 0 USD.
You don't have any saved screeners yet
